Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Before and After CAR-T Cell Therapy in Relapsed or Refractory Large B-cell Lymphomas
NCT06458439Phase 2Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), non-Hodgkin lymphoma (NHL), sponsored by Abramson Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06458439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06458439.